This pivotal new paper, which you can download HERE, describes how biopharmaceutical companies can better leverage existing real-world data (RWD) to improve the costs and efficiencies of R&D and accelerate the timelines of clinical trials without compromising the quality of evidence development, and instead greatly enhance trial feasibility, implementation, and data analysis.

Here, we explore and outline how RWE can be practically applied to pre-clinical research and subsequent trial design and implementation. After reading this whitepaper, you will have a better understanding of how to:

  • Use RWE to generate a feasible and clinically relevant
    hypotheses and refine your patient cohort
  • Leverage genomic data to further tune your patient cohort
  • Optimize clinical trial design
  • Ensure patient availability
  • Assess site feasibility
  • Reduce control arm and recruitment burden
  • And bolster data analysis using a patient-centric tool